Ulcerative colitis

The study tests whether a simple blood-derived index (CRP×NLR) can help identify moderate-to-severe endoscopic inflammation when timely endoscopy is limited in hospitalized UC patients.

Non-invasive fecal lipid markers could help differentiate UC from CD and improve diagnostic molecular profiling in IBD if validated, which may be useful for patients and clinicians seeking less-invasive diagnostic tools.

GI infections—especially CMV—were common in this study and much more frequent in acute severe UC than in remission, suggesting testing for infections can change diagnosis and management during severe flares.

The study evaluates how well first-line 5-ASA therapy achieves modern treatment targets (endoscopic, histologic, and biomarker remission) in real-world UC patients who are clinically in remission. Patients and clinicians...

This study suggests noninvasive vagus nerve stimulation (taVNS) can reduce colonic inflammation and change immune signals regionally in a mouse model of ulcerative colitis—supporting a possible neuroimmune approach worth...

Micronutrient deficiencies are common in IBD and can worsen anemia, healing, and neurologic function. This study shows inpatient testing focuses on B12 while missing other commonly deficient nutrients (B1, B6, zinc),...

Biologics and newer small molecules have markedly changed IBD care and outcomes for many patients, but their population-level impact depends on access, cost, and how they are used. Understanding this helps patients and...

This study addresses whether being on biologic or small‑molecule IBD drugs before colorectal surgery affects short‑term postoperative complications — a practical concern for patients and clinicians planning surgery.

A targeted, pH-sensitive colon delivery system could improve effectiveness and reduce systemic side effects of drugs used for UC by releasing medication in the colon and protecting it from stomach degradation. For people...

The T&W criteria are still used to define severe UC on admission, but relying on them alone may delay recognition of steroid non‑response and escalation decisions. Integrating biomarkers, endoscopy, and imaging can help...

Distinct circulating immune signatures could help differentiate active UC from CD and suggest disease-specific pathways that might guide future biomarkers or therapies.

Better delineation of colitis‑associated neoplasia can improve the chance of complete endoscopic removal and help find residual disease that white‑light imaging may miss.

This study suggests that specific gut bacteria targeted by systemic IgG are associated with UC activity and inflammation, which could eventually help identify microbial signals linked to flares or systemic inflammation.

A colon-targeted 5-ASA pellet could improve delivery of mesalamine to the diseased colon while reducing release in the stomach; that might increase effectiveness or reduce systemic exposure compared with standard...

The probe targets azoreductase-driven hypoxia, a mechanism linked to ulcerative colitis and other hypoxia-associated diseases; a reliable real-time imaging method could help research and eventually guide treatments.

The study suggests a specific stromal and MAPK/EGFR signalling programme linked to prior anti‑TNF failure in ulcerative colitis, which could help explain why some patients are less responsive to later therapies and point...

Preclinical data suggest sodium phenylbutyrate and suramin may reduce inflammation and oxidative stress in a mouse model of ulcerative colitis, pointing to possible therapeutic mechanisms worth further study.

This study presents a targeted immunotherapy approach designed to concentrate an immune‑modulating protein (PD‑L1‑Fc) in the inflamed colon, which could in future reduce systemic side effects of biologic immunomodulators...

People with an ileal pouch after UC/IBDU often struggle with fecal incontinence and reduced quality of life. This trial is testing a noninvasive device (Emsella chair) aimed at improving incontinence and patient-reported...

A new pediatric Phase 3 trial of filgotinib could broaden approved treatment choices for children and teens with moderate-to-severe ulcerative colitis, especially for those who have not responded to or cannot tolerate...

A new oral investigational drug (HRS-7085) is entering early human testing for moderate-to-severe ulcerative colitis. People with UC who have not benefited from approved therapies may be interested in trial options and...

Pouchitis is a common complication after IPAA and noninvasive tools to detect inflammation could make monitoring easier and less burdensome than repeated pouchoscopy. This trial tested whether intestinal ultrasound can...

A large clinical registry can help researchers learn more about IBD patterns, potential causes, and who might be eligible for future clinical trials. For patients, joining may help advance research and make it easier to...

Researchers are testing whether short-term dual therapy with vedolizumab plus tofacitinib can induce remission in people with moderate–severe UC who have failed prior TNF blockers. If effective and safe, this approach...

AI tools could make objective disease assessment faster and more consistent, help detect inflammation beyond what symptoms suggest, and ultimately support more personalized treatment choices for people with Crohn’s...

Depressive disorders—diagnosed using structured clinical interviews—appear to be relatively common in people with IBD, which has implications for screening and referral to mental health care within IBD clinics.

The study addresses a practical question for people with IBD: whether sequencing anti-TNF therapy after a biologic from a different class affects how well the anti-TNF works. Shorter durability — especially in ulcerative...

The study links shared gene-expression patterns between IBD and ankylosing spondylitis and highlights STAT3 as a potential shared biomarker or therapeutic target, which could be relevant for understanding overlapping...

This correction updates duplicated data points and clarifies methods in a preclinical synthetic-biology study about engineered materials that secrete therapeutic proteins for IBD, which affects interpretation and...

Malnutrition risk and nutrition insecurity can affect symptom management and overall health for people with IBD. Understanding barriers and supports helps target practical services (dietitians, social resources, digital...

Targeted release of mesalamine to the colon could increase local drug levels and reduce upper-GI exposure and systemic side effects. New delivery platforms may improve effectiveness for ulcerative colitis without...

The study identifies shared genetic signals and cell types (especially T cells) between ulcerative colitis and psoriasis, which could help explain their clinical co-occurrence and suggest pathways for future research or...

Finding neutralising anti-IL-10 antibodies in a subset of children with IBD may help explain why some patients have more severe, treatment‑resistant disease and points to a potential biomarker for risk stratification.

Pouch-related fistula is a serious late complication after IPAA. The study suggests people with UC who undergo IPAA may have higher fistula risk than patients with FAP, and that inflammatory pouch disease (like...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis and Research and clinical trials. The original article is from Journal of Visualized Experiments.

Shattuck Labs plans to advance a DR3-targeting bispecific antibody (SL-325) into a Phase 2b trial for Crohn's disease, which is relevant to people watching new investigational biologics for IBD. The report is a...

AI could help make IBD assessments (endoscopy, histology, imaging, biomarkers) more objective and faster, which may improve monitoring, treatment selection, and early detection of complications for people with Crohn’s...

If PALI-2108 proves safe and effective in Phase 2 trials, it could add a new oral treatment option for people with ulcerative colitis and Crohn’s disease. Early Phase 1 signals and a funded Phase 2 program mean the...

Growth and new approvals for Skyrizi and Rinvoq may increase treatment options and influence which drugs gastroenterologists prescribe for Crohn’s disease and ulcerative colitis. Changes in approvals, dosing options, and...

The study connects common dietary patterns to self‑reported IBD activity and quality of life, suggesting diet may be linked to symptom burden for people with Crohn’s disease and UC/IBDU.

Researchers used genetics plus single-cell sequencing and ELISA to prioritize plasma protein ratios that may causally relate to ulcerative colitis. If validated in larger studies, such biomarkers could help with...

If you have IBD, the mouth and gums may be part of shared inflammatory pathways with your gut. Periodontitis is associated with higher odds of having IBD in cross-sectional studies and has a modest link to later...

Identifies factors that may raise the chance of developing pouchitis after IPAA — useful for patients considering or recovering from proctocolectomy and for clinicians planning perioperative care or monitoring.

This study aims to identify which clinical or biological factors predict treatment response and serious complications in children with newly diagnosed IBD — information that could help tailor care for pediatric patients...

Hospitalized patients with acute severe ulcerative colitis face high short-term risk of colectomy and need effective rescue strategies; this trial tests a personalized, adaptive approach to inpatient medical therapy and...

This news matters because SL-325 targets the TL1A/DR3 pathway, a novel immune target being tested for Crohn’s disease and UC; early Phase 1 data suggest a tolerable profile and prolonged target blockade that could affect...

Finding a blood biomarker that predicts histologic remission could make disease monitoring less invasive and help guide when colonoscopy is needed for people with ulcerative colitis.

This pilot trial explores a non-drug neuromodulation approach (auricular vagus nerve stimulation) that might influence brain–gut interactions, stress, fatigue, and quality of life in people with IBD in remission....